BPOM Receives WHO Recognition: What are the Benefits for the Health Industry?

BPOM Receives WHO Recognition: What are the Benefits for the Health Industry?

Jakarta, CNBC Indonesia - Indonesia’s National Agency of Drug and Food Control (BPOM) has received recognition from the World Health Organization (WHO), earning WHO Listed Authority (WLA) status for the regulation of medical products, particularly vaccines. This announcement was made at the end of last year and places BPOM alongside leading global regulatory authorities.

This recognition is significant because Indonesia is the first developing country whose regulatory system has been acknowledged as meeting the highest international standards. The WLA status was obtained through a rigorous, science-based evaluation from 2023-2025 and affirms BPOM’s capacity to guarantee the safety, quality, and efficacy of drugs and vaccines.

This achievement has strategic implications for Indonesia, ranging from strengthening the national pharmaceutical industry, increasing exports, enhancing the resilience of the health supply chain, to improving Indonesia’s reputation in global health diplomacy.

With this new recognition, how does BPOM Indonesia stand as a credible, globally-standardized regulatory authority for drugs and food, on par with leading regulatory bodies worldwide? Can this recognition enhance the trust of national stakeholders in the pharmaceutical industry, investors, and global partners in Indonesia’s drug and vaccine supervision system?

How can this status support the strengthening of the national health, pharmaceutical, and vaccine industries by encouraging increased domestic production, expanding access to global markets, and accelerating exports? This recognition is based on science, transparency, and reliability.

To thoroughly explore the impact of WHO recognition, CNBC Indonesia will hold a Health Forum with the theme “BPOM Achieves WLA Status: What are the Benefits for Business Actors?” This forum will be held on Friday, February 27, 2026, from 3:00 PM to 5:00 PM WIB.

The Health Forum will feature several speakers from various stakeholders, including Taruna Ikrar - Head of BPOM, Deputy for Drug, Narcotics, Precursors and Addictive Substances Supervision - William Adi Teja, Director of Bio Farma - Shadiq Akasya, and CEO of Biotis Pharmaceuticals - FX Sudirman.

The speakers will discuss BPOM’s new status and its impact on Indonesia and the health industry. The event will be broadcast live on CNBC Indonesia and streamed on CNBCIndonesia.com.

Stay tuned to cnbcindonesia.com and CNBC Indonesia TV for the latest information on economics and business.